Posts by Steven Chervenick
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA)
There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%. So, there is a need for new treatment combinations with drugs that might exhibit a synergistic interaction with pembrolizumab.
Read More2019 Mesothelioma Treatments in Review
There have been many different advances in medicine benefitting mesothelioma patients, and over the course of 2019, different clinical trials have shown that there is still hope for them. One of the clinical trials in 2019 studied Nivolumab, also called Opdivo, as a first- and second-line treatment for mesothelioma. The trial used nivolumab with an…
Read MoreSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
Read MoreDifferent Mesothelioma and Cancer Support Groups
Many times, when people are diagnosed with mesothelioma, they don’t know where to turn. Such a devastating illness can be very isolating and can even cause depression. It might be hard to handle a mesothelioma diagnosis, but people can have hope and support from around the country and even the world. Different online support groups…
Read MoreOncolytic Viruses with Standard Chemotherapy can Help Mesothelioma Patients
Mesothelioma is a cancer with a poor prognosis. People who are diagnosed do not normally have many options, but can at least have hope because of different clinical trials. Clinical trials can help find new treatments and medications to better help mesothelioma sufferers. A clinical trial in Oslo, Norway is looking at oncolytic viruses to…
Read MoreSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors.
Read MoreTwo Substances Used to Treat Different Cancers Could Potentially Help Mesothelioma Patients
Two drugs could soon be used together to treat the most aggressive form of mesothelioma. Mesothelioma is an incurable cancer with very few options for treatment. Chemotherapy and immunotherapy can be used to extend patients’ lives, but they cannot be used to completely cure the disease. There is still hope though because new treatments are…
Read MoreStudy of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
Read MoreHeated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to treatment (refractory), or has come back (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity. Drugs used in chemotherapy, such as doxorubicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more cells.
Read MoreNew Molecular Compound May Improve Chemotherapy Treatment for those Suffering from Mesothelioma
Researchers from MIT and Duke may have found a way to make chemotherapy treatments more effective. Chemotherapy is usually the first treatment that is used in people diagnosed with cancer. It can be helpful, but cancers can have different responses and resistances to it. This new research can help make chemotherapy more potent when treating…
Read More